Aquyre Biosciences Rebrands as CellTivity™ Scientific, Inc. Expands Facility and Secures Investment to Enhance Focus on Real-Time, Point ofCare, Metabolic Cellular Imaging for Cancer Diagnostics
[Waltham, MA] – [Date] – Aquyre Biosciences, Inc., makers of the Van GoghTM Microscopy System is proud to announce its rebranding to CellTivity Scientific, Inc., a strategic move that underscores the company's dedication to pioneering real-time metabolic cellular activity assessment for cancer diagnostics. This transition aligns with the successful launch of the Van Gogh Microscopy System, which has gained significant traction in the market and is designed to address critical challenges in early cancer detection and diagnosis.
The Van Gogh Microscopy System has driven increased adoption and investment, enabling the company to expand its manufacturing capabilities to meet growing demand. The decision to transition from Aquyre Biosciences to CellTivity Scientific also builds on the legacy of its first-generation product, the CelTivity™ Biopsy System, streamlining brand equity and reinforcing its market presence.
In 1923, Otto Warburg first observed that cancer cells exhibit differential aspects of cellular metabolism relative to normal differentiated cells. Based on this widely accepted science, CellTivity Scientific developed the Van Gogh Microscopy System, which provides real-time metabolic activity assessments of all cells within a biopsy. Viewing cellular morphology plus the metabolic activity of individual cells provides clinicians new and immediate insights during diagnostic procedures.
Lung cancer is a leading cause of cancer-related deaths, with 1 in 5 cases going undiagnosed until advanced stages. Early detection is critical for improving survival rates. Interventional Pulmonologists often struggle to obtain diagnostic biopsy samples, particularly from small or hard-to-reach lung lesions. The Van Gogh Microscopy System enhances biopsy accuracy by delivering immediate feedback on metabolic activity and cellular architecture, increasing diagnostic yield and reducing repeat procedures. Its tissue-agnostic design supports expansion beyond cancer detection in pulmonary applications, including any application where a biopsy is taken, including gastrointestinal(GI) diagnostics and organ transplant assessments, aiming to streamline workflows and improve patient outcomes.
“Our rebranding to CellTivity Scientific reflects our commitment to revolutionizing cancer detection through real-time metabolic imaging,” said Gregory Bowles, President and CEO. “The overwhelming response to the Van Gogh Microscopy System in the pulmonary space has exceeded our expectations, reinforcing its impact on improving diagnostic accuracy. As CellTivity Scientific, we are more driven than ever to expand this groundbreaking technology to every field where biopsies are performed, ensuring clinicians have the tools they need for precise and timely diagnoses.”
To support this rapid growth and increased market demand, CellTivity Scientific has moved into a new, expanded facility, allowing for the scaling ofR&D and manufacturing capabilities. This investment ensures the company can meet production needs, accelerate innovation, and continue advancing real-time metabolic imaging technology for broader clinical applications. Additionally, this expansion has accelerated work at CellTivity Scientific to develop and integrate artificial intelligence (AI) and machine learning (ML) applications into its technology—further improving diagnostic accuracy and efficiency for clinicians.
The company has also launched its new website at [www.celltivity.com],where healthcare professionals and stakeholders can learn more about VanGogh and other advancements.
About CellTivity Scientific
At CellTivity Scientific, our mission is to transform cancer diagnostics by providing innovative solutions that enable real-time, point of care metabolic cellular imaging. We are committed to improving patient outcomes through cutting-edge technology and collaborative partnerships with healthcare professionals. Our flagship product, the Van Gogh Microscopy System, exemplifies this commitment by offering a rapid and precise metabolic biopsy assessment, empowering clinicians to make informed decisions during diagnostic procedures.
